+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neuroendocrine Tumors - Pipeline Review, H2 2019

  • ID: 4901267
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 692 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aadi Bioscience Inc
  • DexTech Medical AB
  • HEC Pharm Co Ltd
  • Merck KGaA
  • Oncology Venture U.S. Inc
  • Rhizen Pharmaceuticals SA
  • MORE
Neuroendocrine Tumors - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors - Pipeline Review, H2 2019, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape.

Neuroendocrine tumor begins in the hormone-producing cells of the body's neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety and gastric ulcer disease. Treatments include surgery, radiation therapy and chemotherapy.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Neuroendocrine Tumors - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroendocrine Tumors (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 29, 31, 2, 11, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Neuroendocrine Tumors (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Neuroendocrine Tumors (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuroendocrine Tumors (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuroendocrine Tumors (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuroendocrine Tumors (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuroendocrine Tumors (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aadi Bioscience Inc
  • DexTech Medical AB
  • HEC Pharm Co Ltd
  • Merck KGaA
  • Oncology Venture U.S. Inc
  • Rhizen Pharmaceuticals SA
  • MORE
Introduction
Neuroendocrine Tumors - Overview
Neuroendocrine Tumors - Therapeutics Development
Neuroendocrine Tumors - Therapeutics Assessment
Neuroendocrine Tumors - Companies Involved in Therapeutics Development
Neuroendocrine Tumors - Drug Profiles
Neuroendocrine Tumors - Dormant Projects
Neuroendocrine Tumors - Discontinued Products
Neuroendocrine Tumors - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Neuroendocrine Tumors, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Neuroendocrine Tumors - Pipeline by Aadi Bioscience Inc, H2 2019
Neuroendocrine Tumors - Pipeline by Advanced Accelerator Applications SA, H2 2019

List of Figures
Number of Products under Development for Neuroendocrine Tumors, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aadi Bioscience Inc
  • Advanced Accelerator Applications SA
  • Akeso Biopharma Inc
  • AnHeart Therapeutics Inc
  • Aquestive Therapeutics Inc
  • Ascil Proyectos SL
  • Beijing Foreland Pharma Co Ltd
  • Bioncotech Therapeutics SL
  • Boehringer Ingelheim International GmbH
  • BriaCell Therapeutics Corp
  • Bristol-Myers Squibb Co
  • Camurus AB
  • CanBas Co Ltd
  • Clarity Pharmaceuticals Pty Ltd
  • Crinetics Pharmaceuticals Inc
  • Dauntless Pharmaceuticals Inc
  • DexTech Medical AB
  • Eli Lilly and Co
  • Enterome Bioscience SA
  • EpicentRx Inc
  • Esanex Inc
  • Esperance Pharmaceuticals Inc
  • Exelixis Inc
  • Foresee Pharmaceuticals Co Ltd
  • GEMoaB Monoclonals GmbH
  • HEC Pharm Co Ltd
  • Hutchison MediPharma Ltd
  • Innovent Biologics Inc
  • INVENT Pharmaceuticals Inc
  • Ipsen SA
  • Jubilant DraxImage Inc
  • Karyopharm Therapeutics Inc
  • Lexicon Pharmaceuticals Inc
  • Lixte Biotechnology Holdings Inc
  • Mateon Therapeutics Inc
  • Merck & Co Inc
  • Merck KGaA
  • Midatech Pharma Plc
  • Millennium Pharmaceuticals Inc
  • MimiVax LLC
  • Mina Therapeutics Ltd
  • Molecular Targeting Technologies Inc
  • Molecular Templates Inc
  • Nanovalent Pharmaceuticals Inc
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • Oncoceutics Inc
  • Oncology Venture U.S. Inc
  • Ono Pharmaceutical Co Ltd
  • Orano Med LLC
  • Pfizer Inc
  • Pharma Mar SA
  • Progenics Pharmaceuticals Inc
  • ProLynx LLC
  • Provectus Biopharmaceuticals Inc
  • Regulaxis SAS
  • Rhizen Pharmaceuticals SA
  • Seneca Therapeutics Inc
  • Shanghai Junshi Bioscience Co Ltd
  • Sichuan Huiyang Life Science and Technology Corp
  • Strongbridge Biopharma plc
  • Suntec Medical (Taiwan) Inc
  • Taiho Pharmaceutical Co Ltd
  • Tarveda Therapeutics Inc
  • Teclison Ltd
  • Trio Medicines Ltd
  • Vanquish Oncology Inc
  • Veana Therapeutics LLC
  • Xencor Inc
Note: Product cover images may vary from those shown
Adroll
adroll